Clene Inc. Prepares for Phase 3 Trials of CNM-Au8 for ALS and MS
Clene Inc. is making significant strides in the development of innovative treatments for neurodegenerative diseases, with a focus on ALS and MS. Learn more about their groundbreaking approach and potential impact.
This news matters as Clene's innovative approach has the potential to transform the treatment of neurodegenerative diseases, impacting the lives of millions. The company's focus on developing new class of drugs offers hope for those suffering from ALS, MS, and other neurodegenerative diseases.
